Normalized Pre-Tax Income: A company's income before income tax expense smoothed out by removing non-recurring items.
Nuvectis Pharma, Inc. (NVCT) had Normalized Pre-Tax Income of $-6.33M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.33M |
|
-- |
|
-- |
|
$6.59M |
|
$-6.59M |
|
$0.26M |
|
$-6.33M |
|
|
Normalized Pre-Tax Income |
$-6.33M |
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.33M |
|
$-6.59M |
|
$-6.59M |
|
21.37M |
|
21.37M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$27.01M |
|
-- |
|
-- |
|
$27.01M |
|
$10.13M |
|
-- |
|
-- |
|
$10.13M |
|
$16.87M |
|
$16.87M |
|
$16.87M |
|
23.88M |
|
| Cash Flow Statement Financials | |
$-7.54M |
|
-- |
|
$15.80M |
|
$18.53M |
|
$26.79M |
|
$8.26M |
|
$3.10M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.66 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.54M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-37.54% |
|
-37.54% |
|
-23.45% |
|
-37.54% |
|
$0.71 |
|
$-0.35 |
|
$-0.35 |
|